Source: Medicines & Healthcare Products Regulatory Agency (GB) Revision Year: 2022 Publisher: Aventis Pharma Limited, 410 Thames Valley Park Drive, Reading, Berkshire, RG6 1PT, UK Trading as: Sanofi, 410 Thames Valley Park Drive, Reading, Berkshire, RG6 1PT, UK
Ketoprofen overall has the properties of a potent non-steroidal anti-inflammatory agent.
It has the following pharmacological effects:
Anti-inflammatory:
It inhibits the development of carageenan-induced abscesses in rats at 1 mg/kg, UV radiation induced erythema in guinea pigs at 6 mg/kg. It is also a potent inhibitor of PGE2 and PFG2oc synthesis in guinea pig and human chopped lung preparations.
Analgesic:
Ketoprofen effectively reduced visceral pain in mice caused by phenyl benzoquinone or by bradykinin following p.o. Administration at about 6 mg/kg.
Antipyretic:
Ketoprofen (2 and 6 mg/kg) inhibited hyperthermia caused by s.c injection of brewer’s yeast in rats and, at 1 mg/kg hyperthermia caused by i.v. administration of anticoagulant vaccine to rabbits.
Ketoprofen at 10 mg/kg i.v. did not affect the cardiovascular, respiratory, central nervous system or autonomic nervous systems.
Ketoprofen is slowly but completely absorbed from Oruvail capsules. Maximum plasma concentration occurs after 6–8 hours. It declines thereafter with a half-life of about 8 hours. There is no accumulation on continued daily dosing. Ketoprofen is very highly bound to plasma protein.
No additional data of relevance to the prescriber.
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
